コーパス検索結果 (1語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 age and HRL histologic results (eg, atypical ductal hyperplasia).
2 , conditional PAF expression induces mammary ductal hyperplasia.
3 ds also display mammary trees with extensive ductal hyperplasia.
4 al scar, fibroadenoma, and areas of atypical ductal hyperplasia.
5 I, 0.4 to 5.6) for the diagnosis of atypical ductal hyperplasia.
6 tively insufficient is described as atypical ductal hyperplasia.
8 +/- 0.38] x 10(-3) mm(2)/sec; n = 13), usual ductal hyperplasia ([1.83 +/- 0.49] x 10(-3) mm(2)/sec;
10 lts in patients with a diagnosis of atypical ductal hyperplasia (ADH) (75 of 6,081 [1.2%]) were revie
11 sess the rate of underestimation of atypical ductal hyperplasia (ADH) and ductal carcinoma in situ (D
12 ity (LOH) on 11q13 (PYGM, INT-2) in atypical ductal hyperplasia (ADH) and various histological types
14 psy revealed carcinoma in 19 (61%), atypical ductal hyperplasia (ADH) in eight (26%), and benign find
15 wo, papilloma with adjacent foci of atypical ductal hyperplasia (ADH) in eight, and well-differentiat
17 nt of percutaneously diagnosed pure atypical ductal hyperplasia (ADH) is an unresolved clinical issue
18 advised for the 143 carcinomas, 25 atypical ductal hyperplasia (ADH) lesions, and five radial scars.
20 cinoma in situ (DCIS), one focus of atypical ductal hyperplasia (ADH), and one atypical lobular hyper
21 simple ductal hyperplasia (SH) and atypical ductal hyperplasia (ADH), are candidate precursors to du
22 landscape of normal breast tissue, atypical ductal hyperplasia (ADH), DCIS and invasive breast cance
23 s well as the co-occurrence rate of atypical ductal hyperplasia (ADH), with 95% CIs were calculated.
26 expression of 14-3-3 zeta begins at atypical ductal hyperplasia, an early stage of breast disease.
27 cinoma in situ were reclassified as atypical ductal hyperplasia and considered false-positive results
28 ductal in morphology and progressed through ductal hyperplasia and ductal carcinoma in situ before i
29 lands from the virgin MTA1s-TG mice revealed ductal hyperplasia and ductal carcinoma in situ, and low
31 e mS100a7a15 was induced exhibited increased ductal hyperplasia and expression of molecules involved
35 pry1 and Spry2 in prostate epithelium causes ductal hyperplasia and low-grade prostatic intraepitheli
36 four histological types: normal cases, usual ductal hyperplasia and low/high grade ductal carcinoma i
37 tion in early tumorigenic lesions, including ductal hyperplasia and mammary intraepithelial neoplasia
40 l and lobular carcinoma in situ and atypical ductal hyperplasia), and 277 controls without these brea
41 east lesions, including focal solid nodules, ductal hyperplasia, and mini-intraductal neoplasm and ad
42 nitiating cells results in the production of ductal hyperplasia, and modulation of Bmi-1 expression i
45 ditional lesions, unfolded lobules and usual ductal hyperplasia, are sometimes considered to be very
46 ith atypia 9% (95% CI: 5%-14%), and atypical ductal hyperplasia associated with CCL 20% (95% CI: 13%-
47 without atypia, CCL with atypia and atypical ductal hyperplasia associated with CCL followed by surgi
48 NB diagnosis of CCL with atypia and atypical ductal hyperplasia associated with CCL, surgical excisio
49 racterized premalignant lesions are atypical ductal hyperplasia, atypical lobular hyperplasia, and lo
52 ession in mammary epithelial cells developed ductal hyperplasia (DH), lobular hyperplasia, and ductal
54 apparent complete lesion removal), atypical ductal hyperplasia diagnosed with percutaneous needle bi
55 re crisis in normal ductal epithelium, usual ductal hyperplasia, ductal carcinoma in situ and invasiv
56 ry tumor virus LTR enhancer causes extensive ductal hyperplasia early in life and mammary adenocarcin
57 ded high-risk lesions, including 21 atypical ductal hyperplasia, eight atypical lobular hyperplasia,
58 ent of premalignant lesions such as atypical ductal hyperplasia, elevated growth factors, or increase
60 tological analysis revealed extensive breast ductal hyperplasia in females of all genotypes after rHR
61 e show that deleting the Tip30 gene leads to ductal hyperplasia in mouse mammary glands early in life
63 sults: fibrocystic changes in four, atypical ductal hyperplasia in two, atypical lobular hyperplasia
67 assigned 500 women with breast IEN (atypical ductal hyperplasia, lobular carcinoma in situ [LCIS], or
68 her malignant or high-risk lesions (atypical ductal hyperplasia, lobular carcinoma in situ, atypical
69 evelopment, and glands were characterized by ductal hyperplasia, luminal filling, and highly disorgan
70 the metastatic pleural effusion and atypical ductal hyperplasia mammary tumor specimens (21MT-1 and 2
72 r periductal inflammatory cell accumulation, ductal hyperplasia, or dysplastic lesions/pancreatic int
73 se lesions such as papillomatosis, papillary ductal hyperplasia, papillary ductal carcinoma in situ (
74 eases QR levels and results in a decrease in ductal hyperplasia, proliferation, oxidative DNA damage
75 Proliferative breast lesions, such as simple ductal hyperplasia (SH) and atypical ductal hyperplasia
77 sed progressively during the transition from ductal hyperplasia to ductal carcinoma in situ to adenoc
80 ion of breast lesions as either benign usual ductal hyperplasia (UDH) or malignant ductal carcinoma i
81 that recapitulates many attributes of "usual ductal hyperplasia" (UDH), a common benign mammary lesio
82 ransgenic (AEBP1(TG)) mice, and the onset of ductal hyperplasia was accelerated in AEBP1(TG) mice fed
84 ased cell division and a distinctive form of ductal hyperplasia with 'squamoid' ghost cell nodules in
87 agen deposition, enlarged ductal structures, ductal hyperplasia with atypical epithelial transcriptom